Using Patient Experience Data and Discrete Choice Experiment to Assess Values of Drugs
Advertisement
Advertisement
Trending on AJMC
1
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
2
5 Ongoing Clinical Trials in Myeloproliferative Neoplasms
3
Defunding Co-Payment Assistance Disrupted nAMD Care
4
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
5